- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
CorMedix Inc (CRMD)
CorMedix Inc stock price live, this page displays NASDAQ CRMD stock exchange data. View the CRMD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the CorMedix Inc real time stock price chart below.
What Is the CorMedix Inc Stock Price Today?
The CorMedix Inc stock price today is 7.270.
What Is the Stock Symbol for CorMedix Inc?
The stock symbol for CorMedix Inc is "CRMD."
What Stock Exchange Does CorMedix Inc Trade On?
CorMedix Inc is listed and trades on the NASDAQ stock exchange.
Is CorMedix Inc a Good Stock to Buy?
Determining whether CorMedix Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CRMD quote. (ISIN: US21900C3088)
What Is the CorMedix Inc Stock Price Today?
The CorMedix Inc stock price today is 7.270.
What Is the Stock Symbol for CorMedix Inc?
The stock symbol for CorMedix Inc is "CRMD."
What Stock Exchange Does CorMedix Inc Trade On?
CorMedix Inc is listed and trades on the NASDAQ stock exchange.
Is CorMedix Inc a Good Stock to Buy?
Determining whether CorMedix Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CRMD quote. (ISIN: US21900C3088)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.145
7.520
52 wk Range
5.600
17.430
CRMD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.1457.520
52 wk Range
5.60017.430
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CRMD Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
14.857
Upside
+104.36%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- CorMedix director Dillione sells $68,800 in shares
- Investing.com
- CorMedix director Dillione sells $68,800 in shares
- Investing.com
- Form 144 CORMEDIX INC. For: 21 January
- Investing.com
- CorMedix Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
CorMedix Inc Company Profile
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
CorMedix Inc SWOT Analysis
Strategic Acquisition | CorMedix's $300M acquisition of Melinta Therapeutics promises portfolio diversification and near-term EPS accretion, reshaping its market position |
Financial Projections | Explore CorMedix's ambitious FY2025 guidance, projecting revenues of $305M-$330M and EBITDA of $150M-$170M, signaling strong growth potential |
DefenCath's Momentum | Delve into DefenCath's Q2 2025 sales of $39M and its potential expansion into the TPN market, highlighting CorMedix's focus on product development |
Analyst Outlook | Citizens Bank sets a $22 price target for CRMD, labeling it "MARKET OUTPERFORM" and underscoring the stock's potential upside |
CorMedix Inc Earnings Call Summary for Q1/2025
- Q1 2025 EPS of $0.32, doubling forecast; revenue at $39.1M, surpassing expectations by $6.75M
- Stock rose 6.3% premarket to $9.599; net income of $20.6M vs. $14.5M loss in Q1 2024
- Revised H1 2025 net revenue guidance to ~$70M; targeting FDA approval for new indication by late 2027
- Strong performance attributed to DefendCath momentum and strategic market expansions
- Analysts maintain Strong Buy consensus; stock targets range from $12 to $19 per share
Last Updated: 2025-05-06, 09:34 a/m
Read Full TranscriptCompare CRMD to Peers and Sector
Metrics to compare | CRMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRMDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 3.5x | −1.1x | −0.6x | |
PEG Ratio | 0.01 | −0.01 | 0.00 | |
Price/Book | 1.5x | 1.1x | 2.6x | |
Price / LTM Sales | 2.7x | 2.6x | 3.4x | |
Upside (Analyst Target) | 106.3% | 84.6% | 41.5% | |
Fair Value Upside | Unlock | 22.4% | 4.4% | Unlock |
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 14.857
(+104.36% Upside)
Earnings
Latest Release
Nov 12, 2025
EPS / Forecast
1.26 / 0.43
Revenue / Forecast
104.28M / 65.92M
People Also Watch
FAQ
What Is the CorMedix (CRMD) Stock Price Today?
The CorMedix stock price today is 7.270
What Stock Exchange Does CorMedix Trade On?
CorMedix is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for CorMedix?
The stock symbol for CorMedix is "CRMD."
What Is the CorMedix Market Cap?
As of today, CorMedix market cap is 572.80M.
What Is CorMedix's Earnings Per Share (TTM)?
The CorMedix EPS (TTM) is 2.25.
When Is the Next CorMedix Earnings Date?
CorMedix will release its next earnings report on Mar 31, 2026.
From a Technical Analysis Perspective, Is CRMD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has CorMedix Stock Split?
CorMedix has split 1 times.
How Many Employees Does CorMedix Have?
CorMedix has 65 employees.
What is the current trading status of CorMedix (CRMD)?
As of Jan 25, 2026, CorMedix (CRMD) is trading at a price of 7.270, with a previous close of 7.440. The stock has fluctuated within a day range of 7.145 to 7.520, while its 52-week range spans from 5.600 to 17.430.
What Is CorMedix (CRMD) Price Target According to Analysts?
The average 12-month price target for CorMedix is USD14.857, with a high estimate of USD18 and a low estimate of USD13. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +104.36% Upside potential.
What Is the CRMD Premarket Price?
CRMD's last pre-market stock price is 7.450. The pre-market share volume is 12,540.000, and the stock has decreased by 0.010, or 0.130%.
What Is the CRMD After Hours Price?
CRMD's last after hours stock price is 7.280, the stock has decreased by 0.010, or 0.140%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.